What Happened?

Shares of genetic testing company Myriad Genetics (NASDAQ: MYGN) jumped 6.9% in the afternoon session after its President and CEO, Samraat Raha, purchased a significant amount of company stock. According to filings, Raha bought 40,000 shares for a total of approximately $200,000, at an average price near $5.00 per share. This purchase increased his direct ownership to 493,104 shares. Such a large buy from a top executive is often viewed by investors as a strong vote of confidence in the company's future direction and value. The move was particularly notable given that reports indicated the company's shares had declined over the previous year.

Is now the time to buy Myriad Genetics? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Myriad Genetics’s shares are extremely volatile and have had 46 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 7 days ago when the stock gained 5.9% on the news that the company announced the launch of its Precise MRD™ test for breast cancer patients and presented at a healthcare conference. The new test, which detects what is known as molecular residual disease, was designed to help doctors monitor patients during cancer treatment. Myriad Genetics initiated the launch with a select number of oncology practices, with plans for a broader commercial rollout across the U.S. later in the year. The development came as the company also presented at the TD Cowen 46th Annual Health Care Conference. This news followed a recent earnings call in which the company reaffirmed its full-year 2026 financial outlook, signaling confidence in its growth.

Myriad Genetics is down 16% since the beginning of the year, and at $5.16 per share, it is trading 50.5% below its 52-week high of $10.41 from March 2025. Investors who bought $1,000 worth of Myriad Genetics’s shares 5 years ago would now be looking at an investment worth $175.82.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.